ACN Newswire
HONG KONG, May 7, 2025 – (ACN Newswire) – Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). This regulatory milestone significantly broadens the treatment population, allowing NEFECON to be used to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression…
Read More
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China
Lyndia Redner
21:21
HONG KONG, May 7, 2025 – (ACN Newswire) – Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). This regulatory milestone significantly broadens the treatment population, allowing NEFECON to be used to reduce the loss of kidney function